MR Fingerprinting-A Radiogenomic Marker for Diffuse Gliomas.

Abstract

Simple SummaryMR imaging of brain tumors is still mainly based on contrast images and 2 quantitative parameters (relative Cerebral Blood Volume and Apparent Diffusion Coefficient). It is time consuming and suffers from inter-scanner variability. MR Fingerprinting is a new approach that relies on the principle that each tissue examined evolves its own unique signal fingerprint within one single short sequence. It provides quantitative information about the tissue and allows the generation of contrast images. The purpose of this study was to evaluate the use of MR Fingerprinting as a radiogenomic marker to differentiate gliomas according to the genotypic marker isocitrate dehydrogenase (IDH) mutation. Based on the results of this study MR Fingerprinting seems to have the potential to differentiate IDH-mutant from IDH-wildtype gliomas, which provides a prognostic factor noninvasively. In general MR Fingerprinting leads to a new area of Neuro MRI with the possibility of acquiring quantitative MRI data in a clinically feasible way using only one single short sequence, which may promote molecular precision imaging.(1) Background: Advanced MR imaging (MRI) of brain tumors is mainly based on qualitative contrast images. MR Fingerprinting (MRF) offers a novel approach. The purpose of this study was to use MRF-derived T1 and T2 relaxation maps to differentiate diffuse gliomas according to isocitrate dehydrogenase (IDH) mutation. (2) Methods: Twenty-four patients with histologically verified diffuse gliomas (14 IDH-mutant, four 1p/19q-codeleted, 10 IDH-wildtype) were enrolled. MRF T1 and T2 relaxation times were compared to apparent diffusion coefficient (ADC), relative cerebral blood volume (rCBV) within solid tumor, peritumoral edema, and normal-appearing white matter (NAWM), using contrast-enhanced MRI, diffusion-, perfusion-, and susceptibility-weighted imaging. For perfusion imaging, a T2* weighted perfusion sequence with leakage correction was used. Correlations of MRF T1 and T2 times with two established conventional sequences for T1 and T2 mapping were assessed (a fast double inversion recovery-based MR sequence (‘MP2RAGE’) for T1 quantification and a multi-contrast spin echo-based sequence for T2 quantification). (3) Results: MRF T1 and T2 relaxation times were significantly higher in the IDH-mutant than in IDH-wildtype gliomas within the solid part of the tumor (p = 0.024 for MRF T1, p = 0.041 for MRF T2). MRF T1 and T2 relaxation times were significantly higher in the IDH-wildtype than in IDH-mutant gliomas within peritumoral edema less than or equal to 1cm adjacent to the tumor (p = 0.038 for MRF T1 mean, p = 0.010 for MRF T2 mean). In the solid part of the tumor, there was a high correlation between MRF and conventionally measured T1 and T2 values (r = 0.913, p < 0.001 for T1, r = 0.775, p < 0.001 for T2), as well as between MRF and ADC values (r = 0.813, p < 0.001 for T2, r = 0.697, p < 0.001 for T1). The correlation was weak between the MRF and rCBV values (r = −0.374, p = 0.005 for T2, r = −0.181, p = 0.181 for T1). (4) Conclusions: MRF enables fast, single-sequence based, multi-parametric, quantitative tissue characterization of diffuse gliomas and may have the potential to differentiate IDH-mutant from IDH-wildtype gliomas.